UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

Impact of Lactobacillus reuteri Supplementation on Anti- Helicobacter pylori Levofloxacin-Based Second-Line Therapy

Ojetti, V; Bruno, G; Ainora, ME; Gigante, G; Rizzo, G; Roccarina, D; Gasbarrini, A; (2012) Impact of Lactobacillus reuteri Supplementation on Anti- Helicobacter pylori Levofloxacin-Based Second-Line Therapy. Gastroenterology Research and Practice , 2012 pp. 1-6. 10.1155/2012/740381. Green open access

[thumbnail of 740381.pdf]
Preview
Text
740381.pdf - Published Version

Download (1MB) | Preview

Abstract

INTRODUCTION: Helicobacter pylori eradication therapy has the potential burden of antibiotic-associated gastrointestinal (GI) side effects. The occurrence of side effects is among the major drawbacks of such regimens. GI manifestations may be related to alterations in the intestinal microflora. Probiotics can prevent or reduce antibiotic-associated side effects and have an inhibitory effect on H. pylori. METHODS: To define the efficacy of Lactobacillus reuteri supplementation in H. pylori eradication and in preventing GI-associated side effects during a second-line levofloxacin triple therapy. 90 H. pylori-positive patients receive for 7 days a second-line triple therapy with esomeprazole, levofloxacin, and amoxicillin with L. reuteri for 14 days (group 1) and without probiotic supplementation (group 2). Each subject received a validated questionnaire to record symptoms everyday for 4 weeks from the start of therapy. H. pylori status and side effects were assessed 6 weeks after treatment. RESULTS: The eradication rate was significantly influenced by probiotic supplementation with L. reuteri (group 1: 36/45, 80%; group 2: 28/45 62%; P < 0.05). The incidence of nausea and diarrhoea in group 1 was significantly lower than that in group 2. CONCLUSION: In H. pylori-positive subjects L. reuteri supplementation increases the eradication rate while reducing the incidence of the most common side effects associated with antibiotic therapy in second-line treatment.

Type: Article
Title: Impact of Lactobacillus reuteri Supplementation on Anti- Helicobacter pylori Levofloxacin-Based Second-Line Therapy
Open access status: An open access version is available from UCL Discovery
DOI: 10.1155/2012/740381
Language: English
Additional information: © 2012 Veronica Ojetti et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
UCL classification: UCL
UCL > Provost and Vice Provost Offices
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine
URI: https://discovery.ucl.ac.uk/id/eprint/10042242
Downloads since deposit
38Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item